| Rank |
2003
Impact Factor |
Impact
2000-04 |
Impact
1981-2004 |
| 1 |
Antiviral Therapy
(5.93) |
J.
Acq. Imm. Def. Syn.
(11.38) |
J. Infect. Diseases
(32.55) |
| 2 |
AIDS
(5.52) |
AIDS
(10.57) |
Infection and Immunity
(27.19) |
| 3 |
Clin. Infect. Diseases
(5.39) |
J. Infect. Diseases
(9.70) |
AIDS
(24.17) |
| 4 |
Emerging Infect. Dis.
(5.34) |
Clin. Infect. Diseases
(9.10) |
J.
Acq. Imm. Def. Syn.
(20.73) |
| 5 |
J. Infect. Diseases
(4.48) |
Infection and Immunity
(8.60) |
Infect. Agents/Disease
(19.15) |
| 6 |
Infection and Immunity
(3.88) |
Lancet Infect. Dis.
(8.12) |
Clin. Infect. Diseases
(17.47) |
| 7 |
JAIDS-J.
Acq. Imm. Def.
(3.68) |
Antiviral Therapy
(7.88) |
AIDS Res. Hum.
Retrov.
(16.08) |
| 8 |
J. Viral Hepatitis
(3.26) |
Emerging Infect. Dis.
(7.57) |
J.
Antimicrob. Chemo.
(14.60) |
| 9 |
J.
Antimicrob. Chemo.
(3.08) |
J.
Antimicrob. Chemo.
(6.05) |
Pediat. Infect. Dis. J.
(12.82) |
| 10 |
Curr. Opin Infect. Dis.
(2.67) |
J. Human Virology
(5.42) |
Emerging Infect. Dis.
(12.64) |